[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"placental-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:placental-dysfunction":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":5},"100636441","cardiometabolic-disease-and-substrate-metabolism-100636441",false,"NCT07565727","Cardiometabolic Disease and Substrate Metabolism","Cardiometabolic Disease, Substrate Metabolism, and Abnormal Placental Pathology: a Multimodal Maternal-Fetal Study","CAP","Inclusion Criteria:\n\n* Age 18-45\n* Any pre-pregnancy BMI\n* At least one high risk OR one moderate risk factor for pre-eclampsia based on ACOG and USPSTF guidelines\n* Willingness to adhere to aspirin therapy\n* Willingness to undergo 2h OGTT for serum collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n* Gestational age at enrollment \\\u003C18 weeks\n* Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n* Type 1 Diabetes Mellitus\n* Current gestational diabetes mellitus\n* Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n* Thrombophilia\n* Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n* Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n* Current or recent use of steroids\n* Current use of prophylactic or therapeutic anticoagulation\n* Medical contraindication to aspirin therapy\n* Molar pregnancy\n* Renal disease\n* Inability or unwillingness to give informed consent\n* Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators","FEMALE","18 Years","45 Years",{"count":21,"type":22},50,"ESTIMATED","9 Months","OBSERVATIONAL","This study's primary purpose is to determine the potential relationship between cardiometabolic disease, specifically insulin resistance (HOMA-IR), and maternal lipid oxidation.",[27,28,29,30,31,32,33,34,35,36,37,38],"Preeclampsia","Gestational Diabetes Mellitus (GDM)","Preeclampsia (PE)","Preeclampsia (PE) Risk","Gestational Diabetes","Gestational Diabetes Mellitus in Pregnancy","Cardiometabolic Diseases","Insulin Resistance","Placental Dysfunction","Pregnancy","Pregnancy Complications","Gestational Complications",[40,41,27,31,42,43,44,45,46],"Cardiometabolic disease","Substrate metabolism","Insulin resistance","HOMA-IR","Lipid oxidation","Placental dysfunction","Chorangiosis","RECRUITING","2026-04-27",{"date":50,"type":51},"2026-05-04","ACTUAL",{"date":53,"type":51},"2025-12-10",{"date":55,"type":22},"2027-08",{"name":57,"class":58},"University of Tennessee Graduate School of Medicine","OTHER"]